Navigation Links
Ambit Biosciences Announces Transition in Company Leadership
Date:7/26/2010

SAN DIEGO, July 26 /PRNewswire/ -- Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that its Board of Directors has completed a thorough executive search and appointed Alan J. Lewis, Ph.D. as Chairman and Chief Executive Officer (CEO) of the Company.   Dr. Lewis has been serving as Executive Chairman of Ambit since March 2010, and will now be responsible for the daily operations of the Company as CEO.

"As Executive Chairman, Alan has made a tremendous impact in guiding the vision and creating the foundation for the Company's future growth," said Steven Elms, managing partner of Aisling Capital, on behalf of Ambit's Board of Directors.  "With more than 30 years industry experience, Alan has a proven track record and brings the business, technical and leadership skills necessary to create value as Ambit advances its promising portfolio through development.  This is a pivotal time for the organization and the Board is confident that with Alan's guidance Ambit will emerge a leader in the biotechnology industry."

Dr. Lewis commented, "Ambit has developed a truly unique approach to kinase drug discovery, and as a result the Company is advancing a deep pool of promising kinase inhibitors for the treatment of oncology, immune and inflammatory diseases with significant unmet medical need.  A major milestone and validation of the Company's approach was the strategic partnership completed in December 2009 with Astellas Pharma to jointly develop and commercialize FLT3 kinase inhibitors, including the Company's lead compound, AC220.  This molecule is in a pivotal Phase 2 study in AML and could be a game-changing therap
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 Follow ... level of each type of cholesterol carrier or lipoprotein ... presence of excessive cholesterol levels in the body, especially ... condition to heart attack and other cardiovascular disorders. Cardiovascular ... therefore testing for cholesterol levels on a regular basis, ...
(Date:9/30/2014)... Basel, Switzerland (PRWEB) September 30, 2014 ... advanced software solutions for drug discovery and ... the FUNGITECT consortium has chosen Genedata Selector ... next-generation sequencing (NGS) data. FUNGITECT is a ... of invasive fungal diseases via individualized anti-fungal ...
(Date:9/30/2014)... 2014 FemCap Inc., www.femcap.com  an innovator ... of a patent No: US, 8,795,248 B2 dated Aug. ... FDA clearance in the U.S., 510(K) K121857, medical device ... patent is related to its menstrual cup with a ... is releasing FemmyCycle Teen, a third menstrual cup to ...
(Date:9/30/2014)... 2014 Lyme Research Alliance ... disease research at universities, today announced the awarding of ... identification, treatment and cure for Lyme and other tick-borne ... most applications in its history—over 20 grant proposals—a 100 ... were pleased to receive so many solid applications from ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3The FemmyCycle 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 2Lyme Research Alliance Awards Nearly $600,000 in New Grants 3Lyme Research Alliance Awards Nearly $600,000 in New Grants 4
... 29 Dawson James Securities, a,full- service investment ... coverage on CryoCor, Inc. (Nasdaq: CRYO ) ... price target of $6.00. John M.,Putnam, Sr. VP-Medical ... CryoCor,s recently FDA-approved cryoablation,system for atrial flutter and ...
... Pharmaxis,(ASX: PXS, Nasdaq: PXSL) today announced that its ... of people with bronchiectasis has met its two,primary ... Data from the 362 subject study demonstrated ... 12 weeks of treatment with Bronchitol,as assessed by ...
... Fund is Largest and First of its Kind in ... support initiatives,that enhance patient safety and quality of care, ... million to fund new and innovative programs,at hospitals, health ... is the largest and first of its kind given ...
Cached Biology Technology:Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 2Phase III Trial Finds Pharmaxis' Bronchitol Effective 3Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 2Cardinal Health Establishes $1 Million Grant Fund for Initiatives That Improve Quality, Safety of Patient Care 3
(Date:9/29/2014)... at home should use ventilation when cooking with a ... after a new study showed an association between gas ... bronchitis. , "In homes where a gas stove was ... is higher than in homes where a gas stove ... professor in the College of Public Health and Human ...
(Date:9/29/2014)... get a bad rap, and understandably so. The grain-of-rice-sized ... of millions of acres in the Western U.S. and ... to popular belief, these pests may not be to ... recently swept through the region. Instead, weather and topography ... fires than these bark-boring beetles. , New research led ...
(Date:9/29/2014)... Dr. Cristin Samper, president and CEO of the ... San Carlos. , The Order of San Carlos ... who have made outstanding contributions to the country, ... An international authority on conservation biology and environmental ... Residence in New York to receive the honor ...
Breaking Biology News(10 mins):Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 2Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 3Tree killers, yes, fire starters, no: Mountain pine beetles get a bad rap, study says 4
... Today, on behalf of the Association for Molecular Pathology ... US Food and Drug Administration,s (FDA) meeting on "Ultra ... to Assess Analytical Validity." As they begin developing their ... officials on many important considerations for evaluating analytical validity. ...
... Sea will promote fish stock recovery and increase fishermen,s incomes, ... York., In the North Sea up to 75 per cent ... result that many fisheries are now badly overfished. In comparison, ... and their fisheries are now some of the most prosperous ...
... LOS ALAMOS, New Mexico, June 22, 2011 Los Alamos ... 2011 R&D100 Awards. Recognized as the "Oscars of Invention" ... 100 proven technological advances of the past year. The ... specific nucleic acids, a spacer fluid for oil wells ...
Cached Biology News:AMP comments at FDA meeting on next-generation sequencing 2Discards ban 'will boost fisheries', says new research 2Los Alamos National Laboratory earns 3 R&D 100 Awards 2Los Alamos National Laboratory earns 3 R&D 100 Awards 3
... (Ribonuclease inhibitor) is a 50 ... inhibit RNase activity. It does ... activity. , Inhibits RNase ... template , Lacks DNA ...
...
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
Biology Products: